• Participants, who, in the opinion of the Investigator, can and will comply with the requirements of the protocol.

• Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any study-specific procedure.

• Healthy participants as established by medical history, clinical examination, and laboratory assessment.

• Participant satisfying screening requirements.

• A male or female between and including 18 and 50 years of age at the time of the first study intervention administration.

• Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy, or post-menopause.

• Female participants of childbearing potential may be enrolled in the trial if the participant:

• Has practiced adequate contraception for 1 month prior to study intervention administration, and

• Has a negative pregnancy test on the day of study intervention administration, and

• Has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.

• Blood sample for simultaneous follicle-stimulating hormone (FSH) and estradiol levels may be collected at the discretion of the Investigator to confirm non-reproductive potential according to local laboratory reference range.

• Genetic testing for HLA-B27 will be performed at Screening and only participants with a negative result will be allowed to participate in the study\*.

⁃ Only for Stage 1.

• For Malawi (Stage 2), the participant lives in Blantyre and has agreed to remain in Blantyre for the study duration.